San Diego, California-based biopharmaceutical company Arena Pharmaceuticals, Inc. just announced they have begun dosing patients in a Phase II clinical program for ralinepag, an orally available, non-prostanoid prostacyclin (IP) receptor agonist, formulated for the treatment of pulmonary arterial hypertension (PAH). Ralinepag has performed favorably in previous preclinical and clinical…
News
Misshapen and bloated mitochondria in the lungs may be the reason why so many elderly develop idiopathic pulmonary fibrosis (IPF), according to a study conducted at the University of Pittsburgh School of Medicine. The research, which will be featured on the cover of the February issue of the…
Thanks to a partnership with IntelGenx Corp (IGXT), Pacific Therapeutics Ltd. is combining two approved drugs to create a once per day tablet to treat pulmonary fibrosis and other diseases that result from excess scarring. Pacific Therapeutics is a clinical stage Specialty Pharmaceutical Company that reformulates and reappropriates FDA approved drugs…
The Pulmonary Hypertension Association (PHA), the country’s leading non-profit organization for pulmonary hypertension (PH), maintains a daily blog on its website called PH Daily Beat, which provides those with PH helpful tips for living with the disease. Recently, the PHA put together…
The Pulmonary Hypertension Association (PHA), the country’s lead non-profit organization for pulmonary hypertension (PH), has just accredited the Adult Pulmonary Hypertension Program at Stanford Medicine as a comprehensive care center. This recognition and endorsement from the PHA makes the Stanford program one of…
A new collaboration between Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) was announced today. The new collaboration aims to develop new small molecule anti-fibrotic therapies and includes an agreement that enables Bristol-Myers Squibb to develop, produce and commercialize the preclinical compounds that can result from this…
Initial results are now available from a national registry that has been established in Russia to track individuals with pulmonary hypertension (PH), including chronic thromboembolic pulmonary hypertension (CTEPH). The research was published in Russian in the journal Terapevticheskii Arkhiv (translated to Therapeutic Archive). PH is a serious disease involving high blood…
United Therapeutics Corporation has signed an agreement with DEKA Research & Development Corp., to continue the development of a breakthrough technology for the subcutaneous delivery of the Remodulin (treprostinil) Injection. The device is expected to offer a potential treatment option for patients who suffer from pulmonary arterial hypertension (PAH) and…
As the year 2014 comes to a close, Pulmonary Hypertension News – your reliable online source for the latest on pulmonary hypertension treatments, events, clinical trials, and research updates – brings you a concise outline of our “Top 14 Pulmonary Hypertension Stories of 2014:” No. 14 – “Pulmonary Hypertension, Other Lung…
Pulmonary arterial hypertension (PAH) is a rare condition characterized by high blood pressure of the lung arteries. It costs a great deal in human life lost and life impairment, but how much money is it costing to treat? A recent study published in BMC Health Services Research attempted to answer…
Biopharmaceutical company and leader in pulmonary arterial hypertension (PAH) therapeutics, Actelion Ltd., has just announced it has filed a New Drug Application (NDA) with the US Food and Drug Administration for innovative PAH treatment Uptravi® (selexipag) — the first oral…
United Therapeutics Corporation recently announced that Medtronic, Inc., the world’s third largest medical device company, has forwarded a pre-market approval application to the U.S. Food and Drug Administration (FDA) for their proprietary SynchroMed® II implantable drug infusion system, along with a new catheter, to be used with United Therapeutics’s Remodulin® (treprostinil) injectable, formulated for intravenous treatment of…
